Business Wire

TII

12.8.2024 13:47:19 CEST | Business Wire | Press release

Share
UAE’s Technology Innovation Institute Revolutionizes AI Language Models With New Architecture

The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has released a new large language model in its Falcon series, the Falcon Mamba 7B. The new model is the no. 1 globally performing open source State Space Language Model (SSLM) in the world, as independently verified by Hugging Face.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240812019509/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

UAE’s Technology Innovation Institute Revolutionizes AI Language Models With New Architecture (Photo: AETOSWire)

As the first SSLM for Falcon, it departs from prior Falcon models which all use a transformer-based architecture. This new Falcon Mamba 7B model is yet another example of the pioneering research the institute is conducting and the breakthrough tools and products it makes available to the community in an open source format.

H.E. Faisal Al Bannai, Secretary General of ATRC and Adviser to the UAE President for Strategic Research and Advanced Technology Affairs, said: “The Falcon Mamba 7B marks TII’s fourth consecutive top-ranked AI model, reinforcing Abu Dhabi as a global hub for AI research and development. This achievement highlights the UAE’s unwavering commitment to innovation.”

For transformer architecture models, Falcon Mamba 7B outperforms Meta’s Llama 3.1 8B, Llama 3 8B, and Mistral’s 7B on the newly introduced benchmarks from HuggingFace. Meanwhile for the other SSLMs, Falcon Mamba 7B beats all other open source models in the old benchmarks and it will be the be first model on HuggingFace’s new tougher benchmark leaderboard.

Dr. Najwa Aaraj, Chief Executive of TII, said: “The Technology Innovation Institute continues to push the boundaries of technology with its Falcon series of AI models. The Falcon Mamba 7B represents true pioneering work and paves the way for future AI innovations that will enhance human capabilities and improve lives.”

State Space models are extremely performant at understanding complex situations that evolve over time, such as a whole book. This is because SSLMs do not require additional memory to digest such large bits of information.

Transformer based models, on the other hand, are very efficient at remembering and using information they have processed earlier in a sequence. This makes them very good at tasks like content generation, however, because they compare every word with every other word, this requires significant computational power.

SSLMs can find applications in various fields such as estimation, forecasting, and control tasks. Similar to the transformer architecture models, they also excel in Natural Language Processing tasks and can be applied to machine translation, text summarization, computer vision, and audio processing.

Dr. Hakim Hacid, Acting Chief Researcher of the TII’s AI Cross-Center Unit, said: “As we introduce the Falcon Mamba 7B, I’m proud of the collaborative ecosystem of TII that nurtured its development. This release represents a significant stride forward, inspiring fresh perspectives and further fueling the quest for intelligent systems. At TII, we’re pushing the boundaries of both SSLM and transformer models to spark further innovation in generative AI.”

Falcon LLMs have been downloaded over 45 million times, proving the outstanding success of the models. Falcon Mamba 7B will be released under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240812019509/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye